Search

Your search keyword '"Chiorean E"' showing total 519 results
Start Over Author "Chiorean E"
519 results on '"Chiorean E"'

5. Use of acupuncture with acupressure in addition to standard-of-care cryotherapy to decrease chemotherapy-associated neuropathy in patients with gastrointestinal malignancies receiving oxaliplatin-based chemotherapy: Study protocol for a randomized, controlled pilot and feasibility study

Author

Cohen, Stacey A., Veleber, Susan, Siman, Jonathan, Guthrie, Katherine A., McMillen, Kerry, Heit, Madilyn, Wadhera, Sonia, Daniels, Jonathan, Hansen, Kjell, Jacoby, Madeline, Taromina, Katherine, Chin, Samantha, Romeo, Melissa, Langley, Blake O., Coveler, Andrew L., Hannan, Lindsay M., King, Gentry, Purcell, Tom, Safyan, Rachael A., Shankaran, Veena, Zhen, David B., Chiorean, E. Gabriela, and Greenlee, Heather

Published
2023
Full Text
View/download PDF

6. Updated results from ERAS-007 plus encorafenib and cetuximab (EC) in patients (pts) with EC-naïve metastatic BRAF V600E colorectal cancer (CRC) in the phase 1b/2 HERKULES-3 study.

Author

Parikh, Aparna Raj, primary, Chiorean, E. Gabriela, additional, Atreya, Chloe Evelyn, additional, Zheng, Lei, additional, Kopetz, Scott, additional, Spira, Alexander I., additional, Spigel, David R., additional, Cui, Yue, additional, Osgood, Ryan, additional, Tran, Rebecca, additional, Morris, Shannon R., additional, and Ulahannan, Susanna Varkey, additional

Published
2024
Full Text
View/download PDF

9. Data from Neoadjuvant Selicrelumab, an Agonist CD40 Antibody, Induces Changes in the Tumor Microenvironment in Patients with Resectable Pancreatic Cancer

Author

Byrne, Katelyn T., primary, Betts, Courtney B., primary, Mick, Rosemarie, primary, Sivagnanam, Shamilene, primary, Bajor, David L., primary, Laheru, Daniel A., primary, Chiorean, E. Gabriela, primary, O'Hara, Mark H., primary, Liudahl, Shannon M., primary, Newcomb, Craig, primary, Alanio, Cécile, primary, Ferreira, Ana P., primary, Park, Byung S., primary, Ohtani, Takuya, primary, Huffman, Austin P., primary, Väyrynen, Sara A., primary, Dias Costa, Andressa, primary, Kaiser, Judith C., primary, Lacroix, Andreanne M., primary, Redlinger, Colleen, primary, Stern, Martin, primary, Nowak, Jonathan A., primary, Wherry, E. John, primary, Cheever, Martin A., primary, Wolpin, Brian M., primary, Furth, Emma E., primary, Jaffee, Elizabeth M., primary, Coussens, Lisa M., primary, and Vonderheide, Robert H., primary

Published
2024
Full Text
View/download PDF

10. Supplementary Table 2 from Neoadjuvant Selicrelumab, an Agonist CD40 Antibody, Induces Changes in the Tumor Microenvironment in Patients with Resectable Pancreatic Cancer

Author

Byrne, Katelyn T., primary, Betts, Courtney B., primary, Mick, Rosemarie, primary, Sivagnanam, Shamilene, primary, Bajor, David L., primary, Laheru, Daniel A., primary, Chiorean, E. Gabriela, primary, O'Hara, Mark H., primary, Liudahl, Shannon M., primary, Newcomb, Craig, primary, Alanio, Cécile, primary, Ferreira, Ana P., primary, Park, Byung S., primary, Ohtani, Takuya, primary, Huffman, Austin P., primary, Väyrynen, Sara A., primary, Dias Costa, Andressa, primary, Kaiser, Judith C., primary, Lacroix, Andreanne M., primary, Redlinger, Colleen, primary, Stern, Martin, primary, Nowak, Jonathan A., primary, Wherry, E. John, primary, Cheever, Martin A., primary, Wolpin, Brian M., primary, Furth, Emma E., primary, Jaffee, Elizabeth M., primary, Coussens, Lisa M., primary, and Vonderheide, Robert H., primary

Published
2024
Full Text
View/download PDF

11. Supplementary Figure 1 from Neoadjuvant Selicrelumab, an Agonist CD40 Antibody, Induces Changes in the Tumor Microenvironment in Patients with Resectable Pancreatic Cancer

Author

Byrne, Katelyn T., primary, Betts, Courtney B., primary, Mick, Rosemarie, primary, Sivagnanam, Shamilene, primary, Bajor, David L., primary, Laheru, Daniel A., primary, Chiorean, E. Gabriela, primary, O'Hara, Mark H., primary, Liudahl, Shannon M., primary, Newcomb, Craig, primary, Alanio, Cécile, primary, Ferreira, Ana P., primary, Park, Byung S., primary, Ohtani, Takuya, primary, Huffman, Austin P., primary, Väyrynen, Sara A., primary, Dias Costa, Andressa, primary, Kaiser, Judith C., primary, Lacroix, Andreanne M., primary, Redlinger, Colleen, primary, Stern, Martin, primary, Nowak, Jonathan A., primary, Wherry, E. John, primary, Cheever, Martin A., primary, Wolpin, Brian M., primary, Furth, Emma E., primary, Jaffee, Elizabeth M., primary, Coussens, Lisa M., primary, and Vonderheide, Robert H., primary

Published
2024
Full Text
View/download PDF

12. Supplementary Figure 2 from Neoadjuvant Selicrelumab, an Agonist CD40 Antibody, Induces Changes in the Tumor Microenvironment in Patients with Resectable Pancreatic Cancer

Author

Byrne, Katelyn T., primary, Betts, Courtney B., primary, Mick, Rosemarie, primary, Sivagnanam, Shamilene, primary, Bajor, David L., primary, Laheru, Daniel A., primary, Chiorean, E. Gabriela, primary, O'Hara, Mark H., primary, Liudahl, Shannon M., primary, Newcomb, Craig, primary, Alanio, Cécile, primary, Ferreira, Ana P., primary, Park, Byung S., primary, Ohtani, Takuya, primary, Huffman, Austin P., primary, Väyrynen, Sara A., primary, Dias Costa, Andressa, primary, Kaiser, Judith C., primary, Lacroix, Andreanne M., primary, Redlinger, Colleen, primary, Stern, Martin, primary, Nowak, Jonathan A., primary, Wherry, E. John, primary, Cheever, Martin A., primary, Wolpin, Brian M., primary, Furth, Emma E., primary, Jaffee, Elizabeth M., primary, Coussens, Lisa M., primary, and Vonderheide, Robert H., primary

Published
2024
Full Text
View/download PDF

13. Supplementary Table 3 from Neoadjuvant Selicrelumab, an Agonist CD40 Antibody, Induces Changes in the Tumor Microenvironment in Patients with Resectable Pancreatic Cancer

Author

Byrne, Katelyn T., primary, Betts, Courtney B., primary, Mick, Rosemarie, primary, Sivagnanam, Shamilene, primary, Bajor, David L., primary, Laheru, Daniel A., primary, Chiorean, E. Gabriela, primary, O'Hara, Mark H., primary, Liudahl, Shannon M., primary, Newcomb, Craig, primary, Alanio, Cécile, primary, Ferreira, Ana P., primary, Park, Byung S., primary, Ohtani, Takuya, primary, Huffman, Austin P., primary, Väyrynen, Sara A., primary, Dias Costa, Andressa, primary, Kaiser, Judith C., primary, Lacroix, Andreanne M., primary, Redlinger, Colleen, primary, Stern, Martin, primary, Nowak, Jonathan A., primary, Wherry, E. John, primary, Cheever, Martin A., primary, Wolpin, Brian M., primary, Furth, Emma E., primary, Jaffee, Elizabeth M., primary, Coussens, Lisa M., primary, and Vonderheide, Robert H., primary

Published
2024
Full Text
View/download PDF

14. Supplementary Figure 3 from Neoadjuvant Selicrelumab, an Agonist CD40 Antibody, Induces Changes in the Tumor Microenvironment in Patients with Resectable Pancreatic Cancer

Author

Byrne, Katelyn T., primary, Betts, Courtney B., primary, Mick, Rosemarie, primary, Sivagnanam, Shamilene, primary, Bajor, David L., primary, Laheru, Daniel A., primary, Chiorean, E. Gabriela, primary, O'Hara, Mark H., primary, Liudahl, Shannon M., primary, Newcomb, Craig, primary, Alanio, Cécile, primary, Ferreira, Ana P., primary, Park, Byung S., primary, Ohtani, Takuya, primary, Huffman, Austin P., primary, Väyrynen, Sara A., primary, Dias Costa, Andressa, primary, Kaiser, Judith C., primary, Lacroix, Andreanne M., primary, Redlinger, Colleen, primary, Stern, Martin, primary, Nowak, Jonathan A., primary, Wherry, E. John, primary, Cheever, Martin A., primary, Wolpin, Brian M., primary, Furth, Emma E., primary, Jaffee, Elizabeth M., primary, Coussens, Lisa M., primary, and Vonderheide, Robert H., primary

Published
2024
Full Text
View/download PDF

15. Supplementary Table 4 from Neoadjuvant Selicrelumab, an Agonist CD40 Antibody, Induces Changes in the Tumor Microenvironment in Patients with Resectable Pancreatic Cancer

Author

Byrne, Katelyn T., primary, Betts, Courtney B., primary, Mick, Rosemarie, primary, Sivagnanam, Shamilene, primary, Bajor, David L., primary, Laheru, Daniel A., primary, Chiorean, E. Gabriela, primary, O'Hara, Mark H., primary, Liudahl, Shannon M., primary, Newcomb, Craig, primary, Alanio, Cécile, primary, Ferreira, Ana P., primary, Park, Byung S., primary, Ohtani, Takuya, primary, Huffman, Austin P., primary, Väyrynen, Sara A., primary, Dias Costa, Andressa, primary, Kaiser, Judith C., primary, Lacroix, Andreanne M., primary, Redlinger, Colleen, primary, Stern, Martin, primary, Nowak, Jonathan A., primary, Wherry, E. John, primary, Cheever, Martin A., primary, Wolpin, Brian M., primary, Furth, Emma E., primary, Jaffee, Elizabeth M., primary, Coussens, Lisa M., primary, and Vonderheide, Robert H., primary

Published
2024
Full Text
View/download PDF

16. Supplementary Table 1 from Neoadjuvant Selicrelumab, an Agonist CD40 Antibody, Induces Changes in the Tumor Microenvironment in Patients with Resectable Pancreatic Cancer

Author

Byrne, Katelyn T., primary, Betts, Courtney B., primary, Mick, Rosemarie, primary, Sivagnanam, Shamilene, primary, Bajor, David L., primary, Laheru, Daniel A., primary, Chiorean, E. Gabriela, primary, O'Hara, Mark H., primary, Liudahl, Shannon M., primary, Newcomb, Craig, primary, Alanio, Cécile, primary, Ferreira, Ana P., primary, Park, Byung S., primary, Ohtani, Takuya, primary, Huffman, Austin P., primary, Väyrynen, Sara A., primary, Dias Costa, Andressa, primary, Kaiser, Judith C., primary, Lacroix, Andreanne M., primary, Redlinger, Colleen, primary, Stern, Martin, primary, Nowak, Jonathan A., primary, Wherry, E. John, primary, Cheever, Martin A., primary, Wolpin, Brian M., primary, Furth, Emma E., primary, Jaffee, Elizabeth M., primary, Coussens, Lisa M., primary, and Vonderheide, Robert H., primary

Published
2024
Full Text
View/download PDF

17. Supplementary Figure 4 from Neoadjuvant Selicrelumab, an Agonist CD40 Antibody, Induces Changes in the Tumor Microenvironment in Patients with Resectable Pancreatic Cancer

Author

Byrne, Katelyn T., primary, Betts, Courtney B., primary, Mick, Rosemarie, primary, Sivagnanam, Shamilene, primary, Bajor, David L., primary, Laheru, Daniel A., primary, Chiorean, E. Gabriela, primary, O'Hara, Mark H., primary, Liudahl, Shannon M., primary, Newcomb, Craig, primary, Alanio, Cécile, primary, Ferreira, Ana P., primary, Park, Byung S., primary, Ohtani, Takuya, primary, Huffman, Austin P., primary, Väyrynen, Sara A., primary, Dias Costa, Andressa, primary, Kaiser, Judith C., primary, Lacroix, Andreanne M., primary, Redlinger, Colleen, primary, Stern, Martin, primary, Nowak, Jonathan A., primary, Wherry, E. John, primary, Cheever, Martin A., primary, Wolpin, Brian M., primary, Furth, Emma E., primary, Jaffee, Elizabeth M., primary, Coussens, Lisa M., primary, and Vonderheide, Robert H., primary

Published
2024
Full Text
View/download PDF

18. SWOG S2303: Randomized phase II/III trial of 2nd line nivolumab + paclitaxel + ramucirumab versus paclitaxel + ramucirumab in patients with PD-L1 CPS ≥ 1 advanced gastric and esophageal adenocarcinoma (PARAMUNE).

Author

Saeed, Anwaar, primary, Colby, Sarah, additional, Oberstein, Paul Eliezer, additional, Duda, Dan G., additional, Agarwal, Rajiv, additional, Figueroa-Moseley, Colmar, additional, Vaidya, Riha, additional, Unger, Joseph M., additional, Guthrie, Katherine A., additional, Rocha, Flavio G, additional, Senthil, Maheswari, additional, Safyan, Rachael A, additional, Wainberg, Zev A., additional, Iqbal, Syma, additional, Chiorean, E. Gabriela, additional, and Philip, Philip A., additional

Published
2024
Full Text
View/download PDF

19. Combining low-dose regorafenib with pembrolizumab for patients with MSI-H colorectal cancer: REGPEM-CRC-01.

Author

Sahin, Ibrahim Halil, primary, Chakrabarti, Sakti, additional, Hsieh, Ronan Wenhan, additional, Bruno, Tullia C., additional, Selfridge, Jennifer Eva, additional, Gorantla, Vikram, additional, Thomas, Roby Antony, additional, Rhee, John C., additional, Tatsuoka, Curtis, additional, Bajor, David L., additional, Mahipal, Amit, additional, Chiorean, E. Gabriela, additional, Tejani, Mohamedtaki Abdulaziz, additional, and Saeed, Anwaar, additional

Published
2024
Full Text
View/download PDF

21. Genomic and immune landscape of biliary tract cancers with ARID1A, PBRM1, and BAP1 alterations.

Author

King, Gentry Teng, primary, Berg, Rachel, additional, Yilma, Binyam, additional, Stoppler, Melissa Conrad, additional, Hsieh, Ronan Wenhan, additional, Safyan, Rachael A, additional, Zhen, David Bing, additional, Coveler, Andrew L., additional, Cohen, Stacey A., additional, Shankaran, Veena, additional, Chiorean, E. Gabriela, additional, and Harris, William Proctor, additional

Published
2024
Full Text
View/download PDF

22. Regorafenib dose-optimisation in patients with refractory metastatic colorectal cancer (ReDOS): a randomised, multicentre, open-label, phase 2 study

Author

Bekaii-Saab, Tanios S, Ou, Fang-Shu, Ahn, Daniel H, Boland, Patrick M, Ciombor, Kristen K, Heying, Erica N, Dockter, Travis J, Jacobs, Nisha L, Pasche, Boris C, Cleary, James M, Meyers, Jeffrey P, Desnoyers, Rodwige J, McCune, Jeannine S, Pedersen, Katrina, Barzi, Afsaneh, Chiorean, E Gabriela, Sloan, Jeffrey, Lacouture, Mario E, Lenz, Heinz-Josef, and Grothey, Axel

Published
2019
Full Text
View/download PDF

23. Efficacy and safety of abemaciclib alone and with PI3K/mTOR inhibitor LY3023414 or galunisertib versus chemotherapy in previously treated metastatic pancreatic adenocarcinoma: A randomized controlled trial

Author

Chiorean, E. Gabriela, primary, Picozzi, Vincent, additional, Li, Chung‐Pin, additional, Peeters, Marc, additional, Maurel, Joan, additional, Singh, Jaswinder, additional, Golan, Talia, additional, Blanc, Jean‐Frédéric, additional, Chapman, Sonya C., additional, Hussain, Anwar M., additional, Johnston, Erica L., additional, and Hochster, Howard S., additional

Published
2023
Full Text
View/download PDF

24. Perioperative Chemotherapy and Chemoradiotherapy for Patients With Resectable and Borderline Resectable Pancreatic Adenocarcinoma

Author

Coveler, Andrew L., primary, Pillarisetty, Venu G., additional, Koh, Wui-Jin, additional, Zhen, David B., additional, Park, James O., additional, King, Gentry G., additional, Sham, Jonathan G., additional, Hannan, Lindsay M., additional, Mann, Gary N., additional, Baker, Kelsey K., additional, Redman, Mary W., additional, Swanson, Paul E., additional, Chiorean, E. Gabriela, additional, and Whiting, Sam H., additional

Published
2023
Full Text
View/download PDF

30. Phase I/II sequencing study of azacitidine, epacadostat, and pembrolizumab in advanced solid tumors

Author

Luke, Jason J., primary, Fakih, Marwan, additional, Schneider, Charles, additional, Chiorean, E. Gabriela, additional, Bendell, Johanna, additional, Kristeleit, Rebecca, additional, Kurzrock, Razelle, additional, Blagden, Sarah P., additional, Brana, Irene, additional, Goff, Laura W., additional, O’Hayer, Kevin, additional, Geschwindt, Ryan, additional, Smith, Michael, additional, Zhou, Feng, additional, and Naing, Aung, additional

Published
2023
Full Text
View/download PDF

34. Figure S6. Serum Cytokines (arm B parts 1 and 2) from Open-label, Phase I Study of Nivolumab Combined with nab-Paclitaxel Plus Gemcitabine in Advanced Pancreatic Cancer

Author

Wainberg, Zev A., primary, Hochster, Howard S., primary, Kim, Edward J., primary, George, Ben, primary, Kaylan, Aparna, primary, Chiorean, E. Gabriela, primary, Waterhouse, David M., primary, Guiterrez, Martin, primary, Parikh, Aparna, primary, Jain, Rishi, primary, Carrizosa, Daniel Ricardo, primary, Soliman, Hatem H., primary, Lila, Thomas, primary, Reiss, David J., primary, Pierce, Daniel W., primary, Bhore, Rafia, primary, Banerjee, Sibabrata, primary, Lyons, Larry, primary, Louis, Chrystal U., primary, Ong, Teng Jin, primary, and O'Dwyer, Peter J., primary

Published
2023
Full Text
View/download PDF

35. Figure S2. Survival Outcomes By Tumor PD-L1 Levels (arm B parts 1 and 2) from Open-label, Phase I Study of Nivolumab Combined with nab-Paclitaxel Plus Gemcitabine in Advanced Pancreatic Cancer

Author

Wainberg, Zev A., primary, Hochster, Howard S., primary, Kim, Edward J., primary, George, Ben, primary, Kaylan, Aparna, primary, Chiorean, E. Gabriela, primary, Waterhouse, David M., primary, Guiterrez, Martin, primary, Parikh, Aparna, primary, Jain, Rishi, primary, Carrizosa, Daniel Ricardo, primary, Soliman, Hatem H., primary, Lila, Thomas, primary, Reiss, David J., primary, Pierce, Daniel W., primary, Bhore, Rafia, primary, Banerjee, Sibabrata, primary, Lyons, Larry, primary, Louis, Chrystal U., primary, Ong, Teng Jin, primary, and O'Dwyer, Peter J., primary

Published
2023
Full Text
View/download PDF

36. Data from Phase 1 Study of the Safety, Tolerability, and Pharmacokinetics of TH-302, a Hypoxia-Activated Prodrug, in Patients with Advanced Solid Malignancies

Author

Weiss, Glen J., primary, Infante, Jeffrey R., primary, Chiorean, E. Gabriela, primary, Borad, Mitesh J., primary, Bendell, Johanna C., primary, Molina, Julian R., primary, Tibes, Raoul, primary, Ramanathan, Ramesh K., primary, Lewandowski, Karen, primary, Jones, Suzanne F., primary, Lacouture, Mario E., primary, Langmuir, Virginia K., primary, Lee, Hank, primary, Kroll, Stew, primary, and Burris, Howard A., primary

Published
2023
Full Text
View/download PDF

37. Supplementary Data from Open-label, Phase I Study of Nivolumab Combined with nab-Paclitaxel Plus Gemcitabine in Advanced Pancreatic Cancer

Author

Wainberg, Zev A., primary, Hochster, Howard S., primary, Kim, Edward J., primary, George, Ben, primary, Kaylan, Aparna, primary, Chiorean, E. Gabriela, primary, Waterhouse, David M., primary, Guiterrez, Martin, primary, Parikh, Aparna, primary, Jain, Rishi, primary, Carrizosa, Daniel Ricardo, primary, Soliman, Hatem H., primary, Lila, Thomas, primary, Reiss, David J., primary, Pierce, Daniel W., primary, Bhore, Rafia, primary, Banerjee, Sibabrata, primary, Lyons, Larry, primary, Louis, Chrystal U., primary, Ong, Teng Jin, primary, and O'Dwyer, Peter J., primary

Published
2023
Full Text
View/download PDF

38. Figure S4 from Open-label, Phase I Study of Nivolumab Combined with nab-Paclitaxel Plus Gemcitabine in Advanced Pancreatic Cancer

Author

Wainberg, Zev A., primary, Hochster, Howard S., primary, Kim, Edward J., primary, George, Ben, primary, Kaylan, Aparna, primary, Chiorean, E. Gabriela, primary, Waterhouse, David M., primary, Guiterrez, Martin, primary, Parikh, Aparna, primary, Jain, Rishi, primary, Carrizosa, Daniel Ricardo, primary, Soliman, Hatem H., primary, Lila, Thomas, primary, Reiss, David J., primary, Pierce, Daniel W., primary, Bhore, Rafia, primary, Banerjee, Sibabrata, primary, Lyons, Larry, primary, Louis, Chrystal U., primary, Ong, Teng Jin, primary, and O'Dwyer, Peter J., primary

Published
2023
Full Text
View/download PDF

39. Figure S5. Tumor Epithelial/Stromal Compartment CD8+ T-Cell Ratio in Tissue-Matched Metastatic Tumors (arm B parts 1 and 2) from Open-label, Phase I Study of Nivolumab Combined with nab-Paclitaxel Plus Gemcitabine in Advanced Pancreatic Cancer

Author

Wainberg, Zev A., primary, Hochster, Howard S., primary, Kim, Edward J., primary, George, Ben, primary, Kaylan, Aparna, primary, Chiorean, E. Gabriela, primary, Waterhouse, David M., primary, Guiterrez, Martin, primary, Parikh, Aparna, primary, Jain, Rishi, primary, Carrizosa, Daniel Ricardo, primary, Soliman, Hatem H., primary, Lila, Thomas, primary, Reiss, David J., primary, Pierce, Daniel W., primary, Bhore, Rafia, primary, Banerjee, Sibabrata, primary, Lyons, Larry, primary, Louis, Chrystal U., primary, Ong, Teng Jin, primary, and O'Dwyer, Peter J., primary

Published
2023
Full Text
View/download PDF

40. Appendix from Randomized Phase II Study of PARP Inhibitor ABT-888 (Veliparib) with Modified FOLFIRI versus FOLFIRI as Second-line Treatment of Metastatic Pancreatic Cancer: SWOG S1513

Author

Chiorean, E. Gabriela, primary, Guthrie, Katherine A., primary, Philip, Philip A., primary, Swisher, Elizabeth M., primary, Jalikis, Florencia, primary, Pishvaian, Michael J., primary, Berlin, Jordan, primary, Noel, Marcus S., primary, Suga, Jennifer M., primary, Garrido-Laguna, Ignacio, primary, Cardin, Dana Backlund, primary, Radke, Marc R., primary, Duong, Mai, primary, Bellasea, Shay, primary, Lowy, Andrew M., primary, and Hochster, Howard S., primary

Published
2023
Full Text
View/download PDF

41. Supplementary Figure Legends from A Phase I Study of an Agonist CD40 Monoclonal Antibody (CP-870,893) in Combination with Gemcitabine in Patients with Advanced Pancreatic Ductal Adenocarcinoma

Author

Beatty, Gregory L., primary, Torigian, Drew A., primary, Chiorean, E. Gabriela, primary, Saboury, Babak, primary, Brothers, Alex, primary, Alavi, Abass, primary, Troxel, Andrea B., primary, Sun, Weijing, primary, Teitelbaum, Ursina R., primary, Vonderheide, Robert H., primary, and O'Dwyer, Peter J., primary

Published
2023
Full Text
View/download PDF

42. Figure S1. Study Design from Open-label, Phase I Study of Nivolumab Combined with nab-Paclitaxel Plus Gemcitabine in Advanced Pancreatic Cancer

Author

Wainberg, Zev A., primary, Hochster, Howard S., primary, Kim, Edward J., primary, George, Ben, primary, Kaylan, Aparna, primary, Chiorean, E. Gabriela, primary, Waterhouse, David M., primary, Guiterrez, Martin, primary, Parikh, Aparna, primary, Jain, Rishi, primary, Carrizosa, Daniel Ricardo, primary, Soliman, Hatem H., primary, Lila, Thomas, primary, Reiss, David J., primary, Pierce, Daniel W., primary, Bhore, Rafia, primary, Banerjee, Sibabrata, primary, Lyons, Larry, primary, Louis, Chrystal U., primary, Ong, Teng Jin, primary, and O'Dwyer, Peter J., primary

Published
2023
Full Text
View/download PDF

43. Table S1 and Table S2 from Randomized Phase II Study of PARP Inhibitor ABT-888 (Veliparib) with Modified FOLFIRI versus FOLFIRI as Second-line Treatment of Metastatic Pancreatic Cancer: SWOG S1513

Author

Chiorean, E. Gabriela, primary, Guthrie, Katherine A., primary, Philip, Philip A., primary, Swisher, Elizabeth M., primary, Jalikis, Florencia, primary, Pishvaian, Michael J., primary, Berlin, Jordan, primary, Noel, Marcus S., primary, Suga, Jennifer M., primary, Garrido-Laguna, Ignacio, primary, Cardin, Dana Backlund, primary, Radke, Marc R., primary, Duong, Mai, primary, Bellasea, Shay, primary, Lowy, Andrew M., primary, and Hochster, Howard S., primary

Published
2023
Full Text
View/download PDF

44. Supplementary Figures S1-S2 from Phase 1 Study of the Safety, Tolerability, and Pharmacokinetics of TH-302, a Hypoxia-Activated Prodrug, in Patients with Advanced Solid Malignancies

Author

Weiss, Glen J., primary, Infante, Jeffrey R., primary, Chiorean, E. Gabriela, primary, Borad, Mitesh J., primary, Bendell, Johanna C., primary, Molina, Julian R., primary, Tibes, Raoul, primary, Ramanathan, Ramesh K., primary, Lewandowski, Karen, primary, Jones, Suzanne F., primary, Lacouture, Mario E., primary, Langmuir, Virginia K., primary, Lee, Hank, primary, Kroll, Stew, primary, and Burris, Howard A., primary

Published
2023
Full Text
View/download PDF

45. Supplementary Table 1 from A Phase I Study of an Agonist CD40 Monoclonal Antibody (CP-870,893) in Combination with Gemcitabine in Patients with Advanced Pancreatic Ductal Adenocarcinoma

Author

Beatty, Gregory L., primary, Torigian, Drew A., primary, Chiorean, E. Gabriela, primary, Saboury, Babak, primary, Brothers, Alex, primary, Alavi, Abass, primary, Troxel, Andrea B., primary, Sun, Weijing, primary, Teitelbaum, Ursina R., primary, Vonderheide, Robert H., primary, and O'Dwyer, Peter J., primary

Published
2023
Full Text
View/download PDF

46. Figure S3. Peripheral T-Cell Proliferation on Treatment (arm B parts 1 and 2) from Open-label, Phase I Study of Nivolumab Combined with nab-Paclitaxel Plus Gemcitabine in Advanced Pancreatic Cancer

Author

Wainberg, Zev A., primary, Hochster, Howard S., primary, Kim, Edward J., primary, George, Ben, primary, Kaylan, Aparna, primary, Chiorean, E. Gabriela, primary, Waterhouse, David M., primary, Guiterrez, Martin, primary, Parikh, Aparna, primary, Jain, Rishi, primary, Carrizosa, Daniel Ricardo, primary, Soliman, Hatem H., primary, Lila, Thomas, primary, Reiss, David J., primary, Pierce, Daniel W., primary, Bhore, Rafia, primary, Banerjee, Sibabrata, primary, Lyons, Larry, primary, Louis, Chrystal U., primary, Ong, Teng Jin, primary, and O'Dwyer, Peter J., primary

Published
2023
Full Text
View/download PDF

47. Supplementary Figure 2 from A Phase I Study of an Agonist CD40 Monoclonal Antibody (CP-870,893) in Combination with Gemcitabine in Patients with Advanced Pancreatic Ductal Adenocarcinoma

Author

Beatty, Gregory L., primary, Torigian, Drew A., primary, Chiorean, E. Gabriela, primary, Saboury, Babak, primary, Brothers, Alex, primary, Alavi, Abass, primary, Troxel, Andrea B., primary, Sun, Weijing, primary, Teitelbaum, Ursina R., primary, Vonderheide, Robert H., primary, and O'Dwyer, Peter J., primary

Published
2023
Full Text
View/download PDF

48. Supplementary Figure 1 from A Phase I Study of an Agonist CD40 Monoclonal Antibody (CP-870,893) in Combination with Gemcitabine in Patients with Advanced Pancreatic Ductal Adenocarcinoma

Author

Beatty, Gregory L., primary, Torigian, Drew A., primary, Chiorean, E. Gabriela, primary, Saboury, Babak, primary, Brothers, Alex, primary, Alavi, Abass, primary, Troxel, Andrea B., primary, Sun, Weijing, primary, Teitelbaum, Ursina R., primary, Vonderheide, Robert H., primary, and O'Dwyer, Peter J., primary

Published
2023
Full Text
View/download PDF

49. Evofosfamide for the treatment of human papillomavirus-negative head and neck squamous cell carcinoma

Author

Jamieson, Stephen M.F., primary, Tsai, Peter, additional, Kondratyev, Maria K., additional, Budhani, Pratha, additional, Liu, Arthur, additional, Senzer, Neil N., additional, Chiorean, E. Gabriela, additional, Jalal, Shadia I., additional, Nemunaitis, John J., additional, Kee, Dennis, additional, Shome, Avik, additional, Wong, Way W., additional, Li, Dan, additional, Poonawala-Lohani, Nooriyah, additional, Kakadia, Purvi M., additional, Knowlton, Nicholas S., additional, Lynch, Courtney R.H., additional, Hong, Cho R., additional, Lee, Tet Woo, additional, Grénman, Reidar A., additional, Caporiccio, Laura, additional, McKee, Trevor D., additional, Zaidi, Mark, additional, Butt, Sehrish, additional, Macann, Andrew M.J., additional, McIvor, Nicholas P., additional, Chaplin, John M., additional, Hicks, Kevin O., additional, Bohlander, Stefan K., additional, Wouters, Bradly G., additional, Hart, Charles P., additional, Print, Cristin G., additional, Wilson, William R., additional, Curran, Michael A., additional, and Hunter, Francis W., additional

Published
2023
Full Text
View/download PDF

50. SWOG 1815: A phase III randomized trial of gemcitabine, cisplatin, and nab-paclitaxel versus gemcitabine and cisplatin in newly diagnosed, advanced biliary tract cancers.

Author

Shroff, Rachna T., primary, Guthrie, Katherine A, additional, Scott, Aaron James, additional, Borad, Mitesh J., additional, Goff, Laura Williams, additional, Matin, Khalid, additional, Mahipal, Amit, additional, Kalyan, Aparna, additional, Javle, Milind M., additional, Aghajanian, Carol, additional, Tan, Benjamin R., additional, Cheema, Puneet S., additional, Patel, Anuj K., additional, Iyer, Renuka V., additional, Kelley, Robin Kate, additional, Thumar, Jaykumar Ranchodbhai, additional, El-Khoueiry, Anthony B., additional, Chiorean, E. Gabriela, additional, Hochster, Howard S., additional, and Philip, Philip Agop, additional

Published
2023
Full Text
View/download PDF

Catalog

Books, media, physical & digital resources
See catalog results